

Appln. No. 10/725,324  
Reply to Office action of December 1, 2003  
Response dated October 14, 2005

### REMARKS

This paper is submitted in response to the Office Action mailed July 18, 2005 for the above-identified patent application. Claims 1-8 are pending in the application. Claims 1, 2, 5 and 6 have been rejected. Claims 3, 4, 7 and 8 have been objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all the limitation of the base claims.

Applicants have amended independent claim 1 to include the recitations of dependent claims 2 and 3. Applicants have also amended independent claim 5 to incorporate the recitations of dependent claims 6 and 7. No new matter has been added.

Claims 1 and 5 have been rejected under 35 U.S.C. 102(a) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Korean Patent No. 2003-0056753 to Kweon *et al.* ("Kweon *et al.*").

Claims 1, 2, 5 and 6 have been rejected under 35 U.S.C. 103(a) as obvious in view of Kweon *et al.* further in view of Japanese Patent No. 62184002 to Tanzawa *et al.* ("Tanzawa *et al.*") and U.S. Patent No. 6,426,077 to Grace.

Claims 1, 2, 5 and 6 have been rejected under 35 U.S.C. 103(a) as obvious in view of Korean Patent No. 2001-01003065 to Lee *et al.* further in view of Tanzawa *et al.*

The Examiner states that the prior art of record does not teach or reasonably suggest a weight-loss composition comprising the claimed ingredients within the amounts recited in claims 3, 4, 7 and 8. As stated above, Applicants have amended independent claim 1 to incorporate the recitations of dependent claims 2 and 3 and independent claim 5 has been amended to incorporate the recitations of dependent claims 6 and 7.

Appln. No. 10/725,324  
Reply to Office action of December 1, 2003  
Response dated October 14, 2005

Therefore, Applicants respectfully submit that the pending claims are now in a condition for allowance. Prompt consideration and allowance of claims 1, 4, 5 and 8 are therefore respectfully requested.

Applicants believe that no additional fees are required in connection with this response. However, if additional fees are required, the Commissioner is hereby authorized to charge any additional payment, or credit any overpayment, to Deposit Account No. 01-2300, referencing Docket Number 027707.00006.

Respectfully submitted,



Rochelle K. Seide, Ph.D.  
Registration No. 32,300  
ARENT FOX PLLC  
1675 Broadway  
New York, NY 10019  
Tel. No. (212) 484-3945  
Fax No. (212) 484-3990  
Customer No. 38485